Notably, the simultaneous knockout of both ADRB2 and COX10, a crucial component in the assembly of cytochrome c oxidase, mitigates the metabolic alterations typically induced by ADRB2 deletion, thereby decelerating prostate cancer progression. The gene discussed is ADRB2; the disease is prostate carcinoma.